Understand the source comparison
Cartalax vs Thymalin: Research Peptide Comparison
The following table compares Cartalax and Thymalin across critical research parameters, tissue selectivity, documented mechanisms, and practical handling requirements. Molecular Structure Tetrapeptide (Ala-Glu-Asp-Gly), 402 Da Polypeptide complex, 1,000–10,000
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- The following table compares Cartalax and Thymalin across critical research parameters, tissue selectivity, documented mechanisms, and practical handling requirements.
- Molecular Structure
- Tetrapeptide (Ala-Glu-Asp-Gly), 402 Da
- Polypeptide complex, 1,000–10,000 Da mixed fractions
- Cartalax's defined sequence enables precise dosing; Thymalin's complexity provides broader immune targets but less molecular specificity
- Primary Tissue Target
- Cartilage, synovial tissue, chondrocytes
- Thymus epithelium, T-lymphocytes
- Completely distinct tissue selectivity. No functional overlap in primary mechanisms
- Documented Mechanism
- Upregulates collagen type II expression, increases proteoglycan synthesis, activates chondrocyte proliferation
- Restores thymic hormone activity, enhances T-cell maturation, increases CD4+ populations
- Cartalax acts at gene expression level in target tissue; Thymalin modulates immune cell differentiation pathways
- Research Applications
- Osteoarthritis models, cartilage regeneration studies, age-related joint decline
- Immunosenescence research, vaccine response enhancement, T-cell function restoration
- Select based on research endpoint. Musculoskeletal vs immune system focus
- Reconstitution Stability
- 28–30 days at 2–8°C
- 14–21 days at 2–8°C
- Thymalin requires faster use post-reconstitution due to polypeptide aggregation risk
- Temperature Sensitivity
- Moderate. Tolerates brief ambient exposure
- High. Polypeptide fractions denature above 8°C with cumulative damage
- Thymalin demands stricter cold chain protocols throughout handling and storage
- Typical Research Dose Range
- 50–200 mcg per administration in rodent models
- 5–10 mg per administration in rodent models
- Thymalin requires 25–50× higher mass doses due to polypeptide mixture vs pure tetrapeptide